Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shohreh Fahimirad has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Hamid Abtahi

    Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran

    6 shared publications
  • Hamid Abtahi

    Molecular and Medicine Research Center, Arak University of Medical Sciences

    4 shared publications
  • Mansour Ghorbanpour

    Department of Medicinal Plants, Faculty of Agriculture and Natural Resources Arak University Arak Iran

    4 shared publications
  • Ali Ganji

    Department of Microbiology and Immunology, School of Medicine, Arak University of Medical Sciences

    2 shared publications
  • Ehsanollah Ghaznavi-Rad

    Molecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran; Department of Medical Laboratory Sciences, Arak School of Paramedicine, Arak University of Medical Sciences, Arak, Iran

    2 shared publications
  • Houshang Alizadeh

    University of Tehran

    2 shared publications

Latest Publications

  • Open Access

    Clinical Evaluation of Chitagel in Chronic Wound Healing: A Complementary Bioactive Gel with Echinacea Extract and Quaternary Ammonium-Modified Chitosan

    by Shohreh Fahimirad, Hasan Jafari, Morteza Sanagooiezadeh Isfahani, Mohammadreza Memarzadeh, Amir Almasi Hashiani, Hamid Abtahi

    Background: Chronic wounds remain a major clinical challenge owing to persistent inflammation, delayed tissue regeneration, and increased susceptibility to infection. Multifunctional wound-healing formulations that simultaneously provide antimicrobial protection, maintain moisture balance, and promote tissue repair may improve clinical outcomes in difficult-to-heal wounds. Objectives: This study evaluated the therapeutic efficacy of Chitagel, a bioactive wound-healing gel containing quaternary ammonium-modified chitosan, Echinacea purpurea extract, polyhexamethylene biguanide (PHMB), glycerin, dexpanthenol, and sorbitol. Methods: This prospective, single-arm interventional clinical study enrolled 80 patients with chronic and non-healing wounds of different etiologies, including diabetic, post-surgical, traumatic, and chronic non-healing wounds, at the Sepahan Wound Care Specialty Clinic (Isfahan, Iran) between 2022 and 2023. All patients received standard wound care in addition to topical Chitagel application. Wound-healing progression was assessed through serial clinical evaluations and digital wound measurements over the treatment period. This exploratory, single-arm, descriptive study was conducted without a control group or blinding. No quantitative cohort-level wound measurements were collected; findings were based on clinical observations and representative cases. Results: Descriptive clinical improvement, including reduced wound size and enhanced granulation tissue, was observed in representative cases across wound categories. No quantitative cohort-level data or statistical comparisons were performed. No major treatment-related adverse events were observed. Chitagel application was associated with reductions in wound size and depth, enhanced granulation tissue formation, observable epithelialization, and improved wound-bed appearance. Favorable healing responses were particularly observed in diabetic and non-healing wounds, which demonstrated progressive wound contraction and tissue regeneration during follow-up. No major treatment-related adverse events were observed during the study period. Conclusions: In this exploratory, uncontrolled, descriptive study, topical Chitagel application was associated with observable wound improvement in selected cases. These preliminary observations may inform future randomized controlled trials. The gel’s multifunctional composition may support wound healing through antimicrobial, moisturizing, and regenerative mechanisms. However, larger, controlled clinical trials with longer follow-up are required to confirm efficacy, establish comparative effectiveness, and further evaluate long-term safety. Trial Registration: Iranian Registry of Clinical Trials (IRCT): IRCT20210510051243N2.

  • Fabrication, characterization and in vitro evaluation of PCL/PVA nanofibers loaded with docetaxel in breast cancer cells

    by Zeynab Zamanzade, Shohreh Fahimirad, Maryam Darvish

    Breast cancer ranks as the second highest cause of mortality among women, and docetaxel (DTX) is a potent anticancer agent whose therapeutic effects can be optimized using nanofibers (NFs)-based drug delivery systems (DDSs). In this study, DTX-loaded NFs were fabricated using polycaprolactone (PCL) and polyvinyl alcohol (PVA) via electrospinning. Scanning electron microscopy (SEM) revealed smooth, bead-free morphology with random fiber orientation. Fourier-transform infrared spectroscopy (FTIR) confirmed successful DTX loading. In vitro drug release assays revealed an initial burst release of approximately 72% within the first 24 h, followed by sustained release over 4 days, resulting in a total of 90% drug release over 7 days. Cytotoxicity studies showed DTX-NFs induced a significant reduction in MCF-7 cell viability, with a 60% decrease in cell viability compared to the control group and a 40% increase compared to free DTX at the same concentration after 24 h. DTX-NFs reduced cell migration by 45% and colony formation decreased by 50% compared to the free DTX treatment. In conclusion, DTX-loaded PCL/PVA NFs demonstrated promising anticancer efficacy, sustained drug release and reduced migration and colony formation in MCF-7 cells, making them a potential strategy for postoperative local chemotherapy and prevention of breast cancer recurrence.


  • Chitosan quaternary ammonium salt-stabilized cerium oxide nanoparticles green-synthesized using Thymus vulgaris extract: multifunctional antibacterial, anticancer, and wound healing applications

    by Samaneh Kamalipooya, Davood Nasrabadi, Hamid Abtahi, Morteza Golmohammadi, Shohreh Fahimirad

    This study presents the synthesis and biological evaluation of chitosan quaternary ammonium salt-stabilized cerium oxide nanoparticles (CS/CeO₂NPs), green-synthesized using Thymus vulgaris (thyme) extract. Characterization through Fourier Transform Infrared Spectroscopy (FTIR), Field-Emission Scanning Electron Microscopy (FESEM), and X-ray Diffraction (XRD) revealed uniform spherical nanoparticles with an average size of 120 nm and crystalline structure with an average crystal size of 28.32 nm. The incorporation of thyme extract into the CS matrix was confirmed. Drug release studies exhibited a biphasic pattern, with a rapid initial release (75.41% in 3 h) followed by a sustained release, achieving 92.56% over 10 days. Antibacterial assays demonstrated dose-dependent efficacy against Staphylococcus aureus, with significant antibacterial activity at concentrations above 60 μg/mL. In vitro anticancer assays revealed potent cytotoxicity against breast cancer (MCF-7) and colon cancer (CT26) cell lines, with 50% inhibition in MCF-7 and over 80% inhibition in CT26 cells at 60 μg/mL. In vivo evaluations further highlighted the therapeutic potential of CS/CeO₂NPs. Wound-healing assays demonstrated accelerated wound closure and enhanced epithelial regeneration in CS/CeO₂NPs-treated rats. In vivo antibacterial assays showed significant bacterial load reduction, particularly against S. aureus, indicating effective infection control. Histological analysis confirmed improved tissue regeneration, reduced inflammation, and enhanced re-epithelialization in CSQ/CeO₂NPs-treated wounds, suggesting efficient wound healing. These results underscore the multi-functional therapeutic potential of CS/CeO₂NPs, highlighting their antibacterial, antioxidant, anticancer, and wound-healing properties. Further research is needed to optimize formulations and elucidate the mechanisms driving their biological activities for clinical applications.


  • Carboxymethyl bacterial cellulose electrospun nanofibers loaded with zinc oxide nanoparticles and polyhexamethylene biguanide for wound healing promotion

    by Neda Molaee, Shohreh Fahimirad, Ali Ganji, Hamid Abtahi

    This study explores the development of a novel wound dressing incorporating bacterial cellulose (BC) produced by Acetobacter xylinum, which was carboxymethylated to enhance its biomedical applicability. Zinc oxide nanoparticles (ZnONPs) were biosynthesized using a green method with Quercus infectoria gall extracts (QIG). The composite dressing, composed of BC and polyurethane (PU) nanofibers, was further functionalized with ZnONPs and polyhexamethylene biguanide (PHMB) to provide enhanced antibacterial and wound healing properties. The PU/BC/ZnONPs/PHMB nanofiber mat exhibited strong antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA), with inhibition zones of 28 and 29 mm for PU/BC/ZnONPs and PU/BC/ZnONPs/PHMB, respectively, surpassing the 12 mm inhibition zone of the Cefoxitin control. The nanofibers had an optimal mean diameter of 71.12 nm, ensuring a high surface area for cell attachment. Mechanical tests confirmed excellent tensile strength and flexibility, while an optimized water vapor transmission rate (∼2000-3000 g/m2/day) facilitated a moist wound environment for enhanced healing. L929 fibroblast studies demonstrated high cell viability (∼95-98%) and enhanced migration, confirming the nanofiber mat's biocompatibility. In vivo wound healing tests showed that PU/BC/ZnONPs/PHMB significantly accelerated wound closure, achieving 90-100% healing by day 10, outperforming PU and PU/BC groups. Bacterial counts were significantly reduced, with complete bacterial inhibition observed by day 5. In conclusion, the PU/BC/ZnONPs/PHMB nanofiber dressing demonstrated superior antibacterial activity, mechanical strength, moisture regulation, and wound healing potential, making it a promising candidate for advanced clinical wound management.


  • Open Access

    Evaluation of Recombinant Ib-AMP4 and Oncorhyncin II Peptides in Synergy for Treating Acinetobacter baumannii Under In Vitro Conditions

    by Majid Safari, Hamid Abtahi, Shima Chehreii, Shohreh Fahimirad

    Background: The rising prevalence of microbial resistance in Acinetobacter baumannii infections has become a significant public health concern. Researchers are exploring antimicrobial peptides (AMPs) as promising alternatives to traditional antibiotics. Among these, Ib-AMP4 and Oncorhyncin II have shown notable antibacterial properties. Objectives: The primary objective of this study was to produce recombinant peptides for Ib-AMP4 and Oncorhyncin II. Additionally, the study aimed to investigate their combined effects against A. baumannii (ATCC 19606). Methods: The study focused on the self-directed expression of synthetic genes encoding Ib-AMP4 and Oncorhyncin II within the Escherichia coliBL21 (DE3) pLysS host expression system. Following purification and optimization, the peptides' biological effectiveness against A. baumannii (ATCC 19606) was evaluated through various assays, including minimum inhibitory concentration (MIC), time-kill, and growth kinetic assessments. Results: The MIC assay confirmed the ability of Ib-AMP4 and Oncorhyncin II to inhibit the growth of A. baumannii, with effective concentrations at 111 µg/mL and 80.25 µg/mL, respectively. Moreover, a synergistic effect was observed when Ib-AMP4 and Oncorhyncin II were combined at 2 × MIC, as demonstrated by the checkerboard method, leading to a rapid reduction in viable cell count. Growth kinetic analysis further revealed a 95% reduction in bacterial turbidity within 5 hours of exposure to the peptide combination. Conclusions: The production of recombinant Ib-AMP4 and Oncorhyncin II peptides showed significant efficacy against A. baumannii. Checkerboard, time-kill, and growth kinetic assays consistently demonstrated their synergistic effects. These findings highlight the potential of combining these peptides as an effective strategy to combat A. baumannii infections.


  • Antimicrobial and Wound Healing Performance of Polycaprolactone Electrospun-Based Nanofibers Incorporating Propolis and Quercus Infectoria Gall Extracts

    by Faezeh Aliee, Shohreh Fahimirad, Ali Ganji, Hamid Abtahi

    Background: A highly effective antibacterial wound dressing was developed in this investigation by developing a novel bioactive functional nanostructure. Methods: Ethanolic extracts of propolis (EEP) and Q.infectoria galls (QIG) were processed to obtain their respective extracts. The antibacterial properties of the individual EEP and QIG extracts and their combined effects were investigated. Based on the antibacterial test results, solutions containing polycaprolactone (PCL), PCL/EEP, PCL/QIG and PCL/EEP/QIG were prepared. These solutions were then used to fabricate nanobased mats through electrospinning. The resulting nanofibers were examined in terms of their physical, chemical and biological traits. In order to assess the wound healing capabilities, in vivo experiments were conducted, wherein the efficacy of the scaffolds in combating Staphylococcus aureus (MRSA) infections on wounds was evaluated. Results: The nanoscale structure of the electrospun nanofibers was confirmed through FESEM analysis, while the successful integration of EEP and QIG in the PCL-based electrospun nanofiber was validated using FTIR. By including both EEP and QIG bioactive extracts in the nanofiber, improved antibacterial and antioxidant activities were achieved without compromising the viability of human fibroblast cells. The use of PCL/EEP/QIG dressings led to wound closure rates of 85% and 100% on the 5th and 15th day of treatment, respectively, demonstrating the effectiveness of the combination of EEP and QIG extracts. Conclusions: The remarkable outcomes have presented encouraging prospects for using PCL/EEP/QIG as a highly effective wound dressing with antibacterial properties in clinical trials.


  • Top Cited Papers
    Open Access

    Aptamers as an approach to targeted cancer therapy

    by Fatemeh Mahmoudian, Azin Ahmari, Shiva Shabani, Bahman Sadeghi, Shohreh Fahimirad, Fahimeh Fattahi

    Conventional cancer treatments can cause serious side effects because they are not specific to cancer cells and can damage healthy cells. Aptamers often are single-stranded oligonucleotides arranged in a unique architecture, allowing them to bind specifically to target sites. This feature makes them an ideal choice for targeted therapeutics. They are typically produced through the systematic evolution of ligands by exponential enrichment (SELEX) and undergo extensive pharmacological revision to modify their affinity, specificity, and therapeutic half-life. Aptamers can act as drugs themselves, directly inhibiting tumor cells. Alternatively, they can be used in targeted drug delivery systems to transport drugs directly to tumor cells, minimizing toxicity to healthy cells. In this review, we will discuss the latest and most advanced approaches to using aptamers for cancer treatment, particularly targeted therapy overcoming resistance to conventional therapies.


  • Top Cited Papers

    Wound healing performance of PCL/chitosan based electrospun nanofiber electrosprayed with curcumin loaded chitosan nanoparticles

    by Shohreh Fahimirad, Hamid Abtahi, Parastu Satei, Ehsanollah Ghaznavi-Rad, Mohsen Moslehi, Ali Ganji